NCT07486323Not yet recruiting
Combined Non-Invasive Brain and Visual Stimulation for Vision Improvement
Evaluation of Combined Non-invasive Brain Stimulation (NIBS) and Visual Tetanic Stimulation (VTS) for Vision Enhancement: A Randomized, Single-blind, Cross-over Trial
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
Glaucoma is a complex disease that can result in progressive vision loss. It is the second leading cause of blindness, accounting for 23% of permanent blindness in Hong Kong. There are no treatments that restore vision lost to glaucoma. This study will examine the effect of transcranial direct current stimulation (NIBS) on improving quality of life, visual function and functional performance in patients with peripheral field loss due to glaucoma.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 10 Mar 2026
- Start date
- 20 Apr 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- The Hong Kong Polytechnic University
- Diseases
- Glaucoma
- NCT number
- NCT07486323
What you commit to
- Study type: Interventional
- Planned participants: 56
- From 20 Apr 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe medical problems (e.g. stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor, peripheral neuropathy), or cognitive disorders (e.g. diagnosed dementia or cognitive impairment);
- Self-reported vestibular or cerebellar dysfunction, history of vertigo;
- Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere motor control;
Age
- Ocular diseases other than glaucoma (e.g. age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participant can hear the instructions clearly during assessments and training);
Other
- Contraindications for non-invasive brain stimulation.
Who the study is looking for
- Age range from 18 to 80 years;
- Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes;
- A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of -6dB) within the central 24 degree of the visual field for at least one eye;
- Best-corrected distance visual acuity of 6/12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved).
- Stable vision and visual field loss for at least 3 months;
- With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function).
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Hong Kong Polytechnic University Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.